Nu Skin Reports Steep Q1 Revenue & EPS Decline, Restructures Debt with Reduced Facilities

summarizeSummary

Nu Skin reported a 12% revenue decline and a sharp drop in EPS for Q1 2026, alongside significant reductions in its customer and sales force metrics. The company also restructured its debt, securing substantially smaller credit facilities with more restrictive covenants, and decided to wind down its BeautyBio business.

check_boxKey Events

• Q1 2026 Financial Results Show Steep Decline

  Revenue decreased 12.0% year-over-year to $320.6 million, and basic EPS plummeted to $0.04 from $2.16 in Q1 2025. The prior year's EPS included a $176.2 million gain from an asset sale.

• Core Business Metrics Deteriorate Significantly

  Customers declined by 14%, Paid Affiliates by 8%, and Sales Leaders by 13% year-over-year, indicating fundamental challenges in the direct-selling model due to macroeconomic factors and transformation headwinds.

• Debt Facilities Significantly Reduced and Covenants Tightened

  The company entered a new credit agreement, replacing a $400 million term loan and $500 million revolving credit facility with a $175 million term loan and a $75 million revolving credit facility. The consolidated leverage ratio covenant was tightened from 2.75:1.00 to 2.25:1.00.

• BeautyBio Business Wind-Down Announced

  Nu Skin decided to wind down its BeautyBio business, resulting in a $1.8 million impairment charge in Q1 2026, following a $25.1 million impairment in Q1 2025 related to the same asset group.

auto_awesomeAnalysis

Nu Skin Enterprises reported a challenging first quarter of 2026, marked by a significant 12.0% year-over-year revenue decline to $320.6 million and a drastic drop in basic EPS to $0.04 from $2.16 in the prior-year period. The 2025 EPS was heavily boosted by a one-time $176.2 million gain from an asset sale, masking underlying operational weaknesses. The core direct-selling business showed substantial deterioration, with Customers, Paid Affiliates, and Sales Leaders declining by 14%, 8%, and 13% respectively, driven by macroeconomic challenges and transformation headwinds. Furthermore, the company restructured its credit facilities, replacing a $400 million term loan and $500 million revolving credit facility with significantly smaller facilities of $175 million and $75 million, respectively, and introduced a more restrictive leverage ratio covenant. This substantial reduction in available credit and tighter covenants signal increased financial pressure and a more cautious lending environment. The decision to wind down the BeautyBio business, following a prior impairment, indicates a failed strategic investment. While operating income improved from a loss to a small profit, and the LifeDNA acquisition shows some growth in a smaller segment, the overall picture is one of significant operational and financial challenges.